Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, August 22, 2012

No added value of CIMT in predicting stroke, MI risk

This is not the rehab CIMT.   The important 4 paragraphs are here, so ask your doctor about your risk.
http://www.theheart.org/article/1436919.do
Common carotid intima-media thickness (CIMT) measurement does not add clinically meaningful information to the Framingham risk score for predicting a person's 10-year risk of first MI or stroke, according to a meta-analysis of relevant studies [1].
"Our results suggest that common CIMT measurements should not routinely be performed in the general population, as the overall added value may be too limited to result in health benefits," the authors say.
"This will come as a surprise for a number of physicians: those who have applied the common CIMT measurement in their routine clinical practice and seen potential benefit," senior author Dr Michiel L Bots (University Medical Center Utrecht, the Netherlands) said in an interview. "Our findings, however, indicate that, on average, common CIMT does not help risk stratification when information of established risk factors is already available."
The study was published in the August 22, 2012 issue of the Journal of the American Medical Association.
Posted by at
Labels: , ,

1 comment:

  1. AnonymousAugust 27, 2012 at 2:46 PM

    Great article. A component of the Carotid IMT test is the plaque evaluation which is not quantified in this study. I'd love to see more research in this area. Vasolabs is putting out an article to address this. I believe Bale/Doneen has as well. It will be interesting to see where the science takes us.

    ReplyDelete

Subscribe to: Post Comments (Atom)